Muscle atrophy is diagnosed through a combination of physical examination, imaging, electrical nerve and muscle testing, and sometimes blood work or biopsy. No single test confirms it on its own. Instead, doctors layer several assessments to determine how much muscle you’ve lost, how it’s affecting your function, and what’s causing it.
Physical Examination and Measurements
The diagnostic process typically starts with a hands-on exam. Your doctor will visually compare both sides of your body for asymmetry, feel muscle bulk, and take circumference measurements of your limbs. Calf circumference is the most reliable simple measurement for predicting overall muscle mass. A calf measurement below 31 cm is a commonly used cutoff suggesting significant loss. Mid-upper arm circumference below 22.5 cm is another red flag.
Grip strength is one of the most widely used screening tools. You squeeze a handheld device called a dynamometer as hard as you can for about five seconds. For men, grip strength below 27 kg suggests probable sarcopenia (age-related muscle loss). For women, the threshold is below 16 kg. The chair stand test offers another quick assessment: if it takes you longer than 15 seconds to stand up from a seated position five times, that points to meaningful muscle weakness.
Doctors also test individual muscle groups manually, asking you to push or pull against resistance while they grade your strength. This helps map which muscles are affected, which is an important clue to the underlying cause.
Functional Performance Testing
Beyond raw strength, doctors often want to see how atrophy is affecting your ability to move in real life. The Short Physical Performance Battery (SPPB) is a well-validated test that scores your gait speed, standing balance, and lower body strength on a 12-point scale. A score of 10 or above indicates low risk of disability. Scores between 7 and 9 suggest moderate limitations, and scores of 4 to 6 indicate severe functional decline. Walking speed on its own is also telling: a gait speed below 0.8 meters per second is one of the criteria used to classify severe sarcopenia.
Imaging: MRI, CT, and Ultrasound
When doctors need to see exactly what’s happening inside the muscle, MRI is the gold standard. It provides high-contrast images that can clearly distinguish muscle tissue from fat, making it possible to measure how much healthy muscle remains and how much has been replaced by fatty tissue. This fat infiltration is a hallmark of progressive atrophy. Advanced MRI techniques can generate fat-fraction maps where each pixel in the image corresponds to a specific percentage of fat, giving a precise picture of deterioration.
MRI can also detect swelling and fibrosis within muscle, and specialized sequences can assess the structural integrity of individual muscle fibers. A value called fractional anisotropy ranges from 0 to 1, where numbers close to 1 mean fibers are intact and numbers approaching 0 indicate significant damage. In neurodegenerative diseases, MRI can even visualize the thinning out of muscle fibers as fat fills in around them. Researchers have also identified a distinctive MRI pattern called muscle “islands,” where small patches of preserved muscle sit within a sea of fat replacement, that can help distinguish whether atrophy stems from nerve damage or from a muscle disease itself.
CT scans offer similar cross-sectional views and are sometimes used when MRI isn’t available or practical, though they involve radiation exposure and provide less soft-tissue contrast.
Ultrasound is a faster, cheaper, portable alternative gaining ground in clinical practice. It measures muscle thickness in real time, both relaxed and contracted. Reduced muscle thickness, defined as falling below the 5th percentile for your age and sex, has 92 to 100% sensitivity for detecting neuromuscular disease and 85% specificity for distinguishing affected patients from healthy individuals. Normal biceps thickness, for reference, averages about 2.5 cm, while the quadriceps averages around 2.1 cm in healthy adults.
Electromyography and Nerve Conduction Studies
One of the most important diagnostic questions is whether your atrophy is neurogenic (caused by nerve damage) or myopathic (caused by a problem within the muscle itself). Electromyography, or EMG, is the primary tool for making this distinction. A thin needle electrode is inserted into the muscle to record its electrical activity at rest and during contraction.
In neurogenic atrophy, the EMG shows increased activity when the needle is first inserted, followed by abnormal spontaneous electrical signals called fibrillation potentials. The individual motor unit signals become larger over time as surviving nerves try to compensate by taking over fibers that lost their nerve supply. The overall pattern of muscle activation is reduced because fewer nerve connections are driving the muscle.
In myopathic atrophy, the picture looks different. Nerve conduction speeds are normal because the nerves themselves are fine. The muscle recruits its motor units early and shows a full activation pattern, but the overall electrical amplitude is lower because individual muscle fibers are weaker or fewer in number. When inflammation is the culprit, as in certain autoimmune conditions, the EMG picks up spontaneous irritability in the muscle membrane.
Nerve conduction studies are typically done alongside EMG. Electrodes on the skin deliver small electrical pulses to measure how fast and how strongly signals travel along your nerves. Together, these tests help pinpoint whether the problem lies in the brain, the spinal cord, the peripheral nerves, the junction between nerve and muscle, or the muscle tissue itself.
Blood Tests
Blood work plays a supporting role in diagnosis. Creatine kinase is the most commonly checked marker. It’s a protein that leaks out of damaged muscle cells into the bloodstream, so elevated levels suggest active muscle breakdown. Myoglobin is another protein released during muscle injury. These markers don’t diagnose atrophy directly, but they help identify whether muscle tissue is actively being damaged and can point toward specific causes like inflammatory muscle disease, metabolic disorders, or toxin exposure.
Doctors may also order inflammatory markers, thyroid function tests, or other panels depending on the suspected cause, since muscle atrophy commonly accompanies conditions like diabetes, cancer, chronic kidney disease, prolonged immobility, and various autoimmune disorders.
Muscle Biopsy
When imaging and electrical testing don’t provide a clear answer, a muscle biopsy can offer a definitive diagnosis. A small sample of muscle tissue is removed, usually from the thigh or upper arm, and examined under a microscope.
The microscopic appearance reveals the type and cause of atrophy with remarkable specificity. In neurogenic atrophy, the pathologist sees clusters of small, angular fibers grouped together. These angulated fibers represent muscle that has lost its nerve supply. Early in the disease, the clusters are small; later, as surviving nerves try to reinnervate larger groups of orphaned fibers, the clusters grow. A pattern called fiber type grouping, where one type of muscle fiber dominates a region instead of the normal checkerboard mix, is another signature of nerve-driven atrophy. Target fibers, which show a distinctive bullseye pattern in cross-section, and pyknotic nuclear clusters also point toward neurogenic causes.
In myopathic conditions, the biopsy shows a different set of changes: variation in fiber size, central placement of nuclei (they’re normally at the edges), and sometimes inflammatory cell infiltration or replacement of muscle with connective tissue. These findings help narrow the diagnosis to specific inherited or acquired muscle diseases.
DEXA and Body Composition Scans
Dual-energy X-ray absorptiometry, better known as DEXA, is widely used to measure total lean body mass and is the standard method for quantifying appendicular skeletal muscle mass (the muscle in your arms and legs). This measurement is divided by your height squared to produce an index. For men, an appendicular lean mass index below 7.0 kg/m² is one of the diagnostic criteria for confirmed sarcopenia under widely used European guidelines. DEXA scans are quick, involve minimal radiation, and provide a whole-body breakdown of fat, muscle, and bone that can be tracked over time to monitor progression or response to treatment.